The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
28
No.
08
February 22, 2002
- U.S. Preventive Services Task Force Recommends Mammograms For Over-40.
- Horvitz Wins BMS Award In Neuroscience; Group Room To Discuss Congressional Issues.
- UICC Receives 1300 Abstracts For Congress In Oslo, Norway.
- Sen. Feinstein To Introduce New National Cancer Act.
- ImClone Offered C225 Deal To Seven Firms Prior To BMS
- NIH Panel Outlines Strategies To Manage Adrenal Tumors.
CCL
Vol.
25
No.
2
February 22, 2002
- Mayo Clinic Study Finds Samarium May Expand Options For Osteosarcoma
- NIH Panel Finds Older GI Imaging Tool Still Useful In Treating Pancreatic Diseases
- Femara Better Suppressor Of Estrogen, Study Finds
- Recombinant Protein C Cuts Risk Of Sepsis Death
- Antidepressant Provides Cool Choice For Hot Flashes
- Increased Lung Cancer Risk After Hodgkin’s Treatment
- Clinical Trials Approved By NCI Last Month Listed
TCL
Vol.
28
No.
09
March 01, 2002
- New NCI Director Plans Greater Support For Translational Research, Collaboration.
- HHS Names Crawford FDA Deputy Commissioner; Williams Appointed Deputy For Oncology Division.
- French Legion d’Honneur Bestowed On Hortobagyi.
- Mammography Summit Planned For June In Milan.
- Urgent Need For New Drugs To Treat Pre-Cancers: AACR.
- Pharmacia Says SU5416 Doesn’t Benefit Colorectal Cancer Patients, Closes Trial.
- FDA Approves Novartis Drug Zometa For Multiple Myeloma And Bone Mets.
- American Home Products Changes Name To Wyeth.
- Three Institutes To Test BioMicro’s Microarray Product. GlycoDesign Allowed Patent For Cancer Drug GD0039.
TCL28 March 8 Special Report
- How ImClone's "Hot" New Drug Got Cold Shoulder From FDA
- FDA Says ImClone Data Insufficient To Evaluate Colorectal Cancer Drug C225.
- ImClone “Screwed Up,” CEO Waksal Tells Conference; Stock Plunges.
- Congressional Committee, SEC Probe ImClone’s Statements To Shareholders.
- BMS Demands Resignation Of Two ImClone Executives
- Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.
- Retrospective Data Clean-up Can't Help C225 Phase II Trial; Protocol Far Too "Fuzzy"
- ImClone Protocol Generates More Questions Than Answers
- Phase III Trial Would Give Clearer Picture of C225 Role
- ImClone Offered C225 Deal To Seven Firms Prior To BMS
- Waksals Keep ImClone Jobs, BMS Pumps $200M Into C225
TCL
Vol.
28
No.
12
March 22, 2002
- Senators Tie Medicare Oral Drug Payment to Ending Markup on Infused Drugs
- Bass & Howes Bought By DDB Seattle
- Surgical Oncologists Honor HHS Secretary
- Medical Advances Not Driven Entirely By Science, Author Physician Barron Lerner Tells Journalists
- Evidence Too Weak to Link Agent Orange, Cancer, IOM Says
- IARC Says Evidence Supports Mammography Screening For 50-69, Limited Evidence For 40-49
- Funding Opportunities.
